Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Abstract: The methods and results of a set of cost-utility analyses conducted for the NICE Non-Alcoholic Fatty Liver Disease (NAFLD) and Cirrhosis guidelines, which were published in July 2016. These Markov models cover various diagnostic, and surveillance questions, including who should be tested, with which test and how frequently.

Cohorts included NAFLD, alcoholic liver disease, hepatitis B and hepatitis C. This presentation will focus on people with or at risk of NAFLD. The discussion will touch upon:

•             The complexity of disease pathway modelling

•             Interaction between patient choice and the  results of cost-effectiveness analysis

•             Incorporation of multiple NICE Single Technology Appraisals in to a clinical guideline model.

Cost-effectiveness modelling of the liver disease pathway. Lefteris Floros, Health Economist, Royal College of Physicians, LondonBiography: Having an academic background in economics and healthcare management, Lefteris has spent his career so far between providing methodological support to researchers applying for NIHR funding and developing national clinical guidelines primarily in the areas of liver disease and prisons’ healthcare.